Rapirosiran
Rapirosiran (ALN-HSD) is a HSD17β13-targeting siRNA. Rapirosiran can be used for the research of metabolic dysfunction-associated steatohepatitis.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 2755196-97-3
- Molecular Weight:16307.22
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Alle 17β-HSD Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Rapirosiran can silence HSD17β13 in the liver, thereby reducing free fatty acid levels[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS. Nr. 2755196-97-3
-
Molecular Weight 16307.22
-
SMILES
[Rapirosiran]
-
Synonyms
ALN-HSD; ALN-288996; AD-288996
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
- Rapirosiran
- 2755196-97-3
- ALN-HSD
- ALN-288996
- AD-288996
- ALN288996
- ALN 288996
- ALN-288996
- AD288996
- AD 288996
- AD-288996
- 17β-HSD
- Small Interfering RNA (siRNA)
- ESC-GalNAc-conjugated agent
- metabolic dysfunction-associated steatohepatitis
- non-alcoholic steatohepatitis
- hepatic HSD17β13 mRNA
- HSD17β13
- NASH patients
- healthy adults
- Inhibitor
- inhibitor
- inhibit